The new US patent entitled, ‘Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases,’ would provide protection until 2023.
Agennix chief financial officer Torsten Hombeck said this patent further strengthens their intellectual property position for talactoferrin in a key market and, importantly, covers the use of talactoferrin in its lead indication, non-small cell lung cancer.
"We are pleased to have recently completed enrollment in the FORTIS-M Phase III registration trial evaluating talactoferrin for this use," Hombeck said.